Progression of ischaemic stroke and excitotoxic aminoacids

doi:10.1016/S0140-6736(96)04453-4

The Lancet

Volume 349, Issue 9045, 11 January 1997, Pages 79-82

https://doi.org/10.1016/S0140-6736(96)04453-4 Get rights and content

Summary

Background

Mechanisms involved in progression of stroke are little understood. Studies in animals have shown an association between neuronal death mediated by excitatory aminoacids and deterioration in focal cerebral ischaemia. We looked for an association between concentrations of glutamate and glycine in plasma and cerebrospinal fluid (CSF) and early progression in a prospective study of 128 patients with acute ischaemic stroke.

Methods

Of 556 consecutive admissions to our emergency unit, 128 eligible patients with ischaemic stroke were included in our study. Blood and CSF samples were taken within the first 24 h from stroke onset when cerebral oedema had been excluded on a previous cranial computed tomography. Ischaemic stroke was judged to be in progression if the Canadian stroke scale score (1·5=maximum neurological deficit, 10=no deficit) fell by 1 or more points during the first 48 h after inclusion. Glutamate and glycine concentrations in plasma and CSF were measured by high-performance liquid chromatography. The effect of plasma and CSF glutamate concentrations on progression was analysed by logistic regression.

Findings

43 (33·6%) patients had progressing ischaemic stroke. Concentrations of glutamate and glycine in plasma and CSF were higher in patients with progressing stroke than in those with stable cerebral infarcts (p<0·0001). There was a significant linear correlation between CSF and plasma concentrations of glutamate (r=0·79, p<0·001). The positive predictive value of a plasma glutamate concentration of more than 200 μmol/L for progression of ischaemic stroke was 97% (95% CI 85–100). Glutamate concentrations of more than 200 μmol/L in plasma and of more than 8·2 μmol/L in CSF were independently and significantly associated with progression of neurological deficit (26·1 [6·9–98·6] and 40·9 [7·6–220], respectively).

Interpretation

Early neurological progression of acute ischaemic stroke is associated with high concentrations of glutamate in blood and CSF. Measurement of plasma glutamate may be useful for the early detection of those patients with acute stroke who will deteriorate during 48 h after onset.

Introduction

Progression of acute stroke is a common event that increases mortality and functional disability.1, 2, 3 The mechanisms involved in progression are little understood, and there are no good predictors of progression in cerebral infarct.1, 2, 4 A better understanding of the mechanisms involved in progression could lead to the development of new drugs to stop or prevent progression during the first hours after onset of cerebral ischaemia. Asplund⁵ has suggested that delayed neuronal death mediated by the accumulation of glutamate and other excitatory aminoacids in extracellular spaces may be a cause of progression in experimental focal ischaemia. Glutamate contributes to neuronal injury in the ischaemic brain by catalysing excessive activation of N-methyl-D-aspartate (NMDA) and AMPA receptors, which increases intracellular calcium and activation of catabolic processes, and leads to cell death.6, 7 An alternative explanation for glutamate-mediated injury is hypoxia due to the spread of peri-infarct depression-like depolarisations, triggered in the core of the ischaemic infarct.⁸ Glutamate is released in high concentrations in the penumbral cortex—a region of reduced perfusion in which neurons are viable for some time after onset of ischaemia⁹—particularly if blood flow is reduced for a long time.¹⁰ Butcher et al¹⁰ have shown that the amount of glutamate released during experimental ischaemia correlates positively with the infarct size.¹⁰ Thus, glutamate toxicity may have a role in the progression of penumbra to infarction. Glycine, the concentration of which increases progressively with time in the ischaemic focus,¹¹ is needed for glutamate-induced activation of the NMDA channel, and could exacerbate the harmful effect of glutamate in the ischaemic border zones.¹²

Despite the experimental evidence of injury mediated by excitatory aminoacids in cerebral ischaemia, there are no clinical studies of excitotoxic damage in the progression of stroke. In our prospective study, we analysed the association between concentrations of glutamate and glycine in plasma and cerebrospinal fluid (CSF) and early progression of neurologial deficit in patients with acute ischaemic stroke.

Section snippets

Methods

Between October, 1992, and September, 1994, we conducted a prospective study of the role of excitatory aminoacids in progression of ischaemic stroke. Of 556 consecutive admissions to our emergency unit for a first-documented hemispheric cerebral infarct, 128 patients were included in the study. Our protocol was approved by the ethics committee of the Hospital Xeral de Galicia. Inclusion criteria were: admission delay (from onset of symptoms to admission) of less than 24 h; diagnosis of

Results

Of the 128 patients, 43 (33·6%) had progressing ischaemic stroke. Table 1 shows demographic data, clinical characteristics at admission, blood pressure 24 h after inclusion, and infarct size on cranial computed tomography 4–7 days after admission for patients with progressing or stable ischaemic stroke. Patients with progressing ischaemic stroke were significantly older, were seen later by the neurologist, had more severe initial stroke, and higher body temperature and concentrations of serum

Discussion

Although several causes have been associated with progression of acute stroke,¹⁷ most mechanisms of early deterioration are not known. Cerebal oedema, haemorrhagic transformation of cerebral infarct, and arterial occlusions without a good collateral blood supply account for only some cases of early deterioration.1, 2 High and low systolic blood pressure, raised blood sugar concentration at admission, and early signs of cerebral infarct on cranial computed tomography have also been associated

References (32)

HS Jørgensen et al.
Effect of blood pressure and diabetes on stroke in progression
Lancet
(1994)
C Robert et al.
Formulas for threshold computations
Comput Biomed Res
(1991)
JA Kemp et al.
The glycine site of the NMDA receptor-five years on
Trends Pharmacol Sci
(1993)
J Reith et al.
Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome
Lancet
(1996)
A Dávalos et al.
Deteriorating ischemic stroke: risk factors and prognosis
Neurology
(1990)
D Toni et al.
Progressing neurological deficit secondary to acute ischemic stroke: a study on predictability, pathogenesis and prognosis
Arch Neurol
(1995)
M Britton et al.
Progression of stroke after arrival at hospital
Stroke
(1985)
K Asplund
Deterioration of acute stroke
KA Hossmann
Mechanisms of ischemic injury: is glutamate involved?
BK Siesjo
Pathophysiology and treatment of focal cerebral ischemia: part I: pathophysiology
J Neurosurg
(1992)

KA Hossmann

Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised

Brain Pathol

(1994)

K Takagi et al.

Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopatahology

J Cereb Blood Flow Metab

(1993)

SP Butcher et al.

Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion

Stroke

(1990)

K Matsumoto et al.

Elevation of neuroactive substances in the cortex of cats during prolonged focal ischemia

J Cereb Blood Flow Metab

(1993)

JW Johnson et al.

Glycine potentiates the NMDA response in cultured mouse brain neurons

Nature

(1987)

HP Adams et al.

Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial

Stroke

(1993)

Cited by (319)

New Perspectives in Neuroprotection for Ischemic Stroke
2024, Neuroscience
The constant failure of new neuroprotective therapies for ischemic stroke has partially halted the search for new therapies in recent years, mainly because of the high investment risk required to develop a new treatment for a complex pathology, such as stroke, with a narrow intervention window and associated comorbidities. However, owing to recent progress in understanding the stroke pathophysiology, improvement in patient care in stroke units, development of new imaging techniques, search for new biomarkers for early diagnosis, and increasingly widespread use of mechanical recanalization therapies, new opportunities have opened for the study of neuroprotection. This review summarizes the main protective agents currently in use, some of which are already in the clinical evaluation phase. It also includes an analysis of how recanalization therapies, new imaging techniques, and biomarkers have improved their efficacy.
Plasma Amino Acid Neurotransmitters and Ischemic Stroke Prognosis: A Multicenter Prospective Study
2023, American Journal of Clinical Nutrition
Plasma amino acid neurotransmitter dysregulation is suggested to be implicated in the development of ischemic stroke, but its prognostic value for ischemic stroke remains controversial.
We aimed to prospectively investigate the associations between plasma amino acid neurotransmitters levels and adverse outcomes after ischemic stroke in a large-scale multicenter cohort study.
We measured 4 plasma amino acid neurotransmitters (glutamic acid, aspartic acid, gamma-aminobutyric acid, and glycine) among 3486 patients with ischemic stroke from 26 hospitals across China. The primary outcome is the composite outcome of death or major disability (modified Rankin Scale score ≥3) at 3 mo after ischemic stroke.
After multivariate adjustment, the odds ratios of death or major disability for the highest versus the lowest quartile were 2.04 (95% confidence interval [CI]: 1.60,2.59; P-trend < 0.001) for glutamic acid, 2.03 (95% CI: 1.59, 2.59; P-trend < 0.001) for aspartic acid, 1.35 (95% CI: 1.06, 1.71; P-trend = 0.016) for gamma-aminobutyric acid, and 0.54 (95% CI: 0.42, 0.69; P-trend < 0.001) for glycine. Each standard deviation increment of log-transformed glutamic acid, aspartic acid, gamma-aminobutyric acid, and glycine was associated with a 34%, 34%, and 9% increased risk, and a 23% decreased risk of death or major disability, respectively (all P < 0.05), in a linear fashion as indicated by spline regression analyses (all P for linearity < 0.05). Addition of the 4 plasma amino acid neurotransmitters to conventional risk factors significantly improved the risk reclassification, as evidenced by integrated discrimination improvement and net reclassification improvement (all P < 0.05).
Increased glutamic acid, aspartic acid, and gamma-aminobutyric acid and decreased glycine in plasma are associated with adverse outcomes after ischemic stroke, suggesting that plasma amino acid neurotransmitters may be potential intervention targets for improving prognosis of ischemic stroke.
The CATIS trial was registered at clinicaltrials.gov (registration number: NCT01840072; URL: ===https://clinicaltrials.gov/ct2/show/NCT01840072?cond=NCT01840072&draw=2&rank=1)
Neuroprotection Following Stroke
2022, Comprehensive Pharmacology
Being a major cause of mortality and disability worldwide, stroke represents a serious unmet medical need. In fact, currently approved therapies for acute ischemic episodes only rely on tissue reperfusion through pharmacological thrombolysis and/or endovascular thrombectomy. Recent innovative imaging approaches have revolutionized the standard care, by widening the time-window for the intervention (up to 24 h after stroke onset), thus increasing the number of patients that can actually benefit from reperfusive therapies. Nevertheless, removing the original cause of ischemia is not sufficient to fully restore cerebral function, while blocking the progression of brain damage through effective neuroprotective strategies represents a desirable aim. However, during the last three decades, virtually all the strategies aimed at targeting the processes involved in the ‘ischemic cascade’, including excitotoxicity, oxidative stress and inflammation, have failed in clinical trials for excess toxicity or lack of efficacy. Recent advances in our understanding of ischemic stroke pathobiology, together with a critical re-assessment of failed trials, have led to the development of novel encouraging approaches that include pharmacological agents (e.g., memantines, uric acid, minocycline, fingolimod, citicoline, etc.) and non-pharmacological interventions (e.g., hypothermia, post-conditioning, brain stimulation). Clinical trials are currently ongoing to assess the benefits of these promising strategies that have revitalized the potential of neuroprotection in stroke.
Methanol extract of Ficus platyphylla decreases cerebral ischemia induced injury in mice
2021, Journal of Ethnopharmacology
Extracts of the stem bark of Ficus paltyphylla (FP) are used in the Nigerian traditional medicine to manage psychoses, depression, epilepsy, pain, and inflammation. Our previous studies revealed that the methanol extract of FP ameliorate body core temperature.
A number of pharmacological agents that utilize mechanisms that enhanced neuronal survival and/or neural regeneration have been developed for the treatment of stroke. Hypothermia protects the brain from damage caused by ischemia by attenuating destructive processes such as neuroinflammation, excitotoxicity, blood-brain barrier disruption, apoptosis, and free radical formation following cerebral ischemia. In the present study, we examined the neuroprotective potential of FP on permanent occlusion of the middle cerebral artery (MCAO)-induced ischemia in mice.
C57Bl mice were subjected to MCAO. FP was administered 1 h prior to and immediately after surgery. The brains were collected 24 h later and infarct volumes were measured using immune-histochemical staining, DAPI, NeuN, synaptophysin, and NR2B were quantified.
Administration of FP prior to MCAO significantly reduced infarct volume, with no effect on infarct volume immediately after MCAO. Higher numbers of cells and neurons were observed in the peri-infarct area in both groups of mice. FP-induced hypothermia protected tissue in the peri-infarct region from synaptophysin reduction. NMDA receptor 2 (NR2B) immunoreactivity is enhanced by MCAO, with no difference observed in both sham-operated and FP-induced hypothermia groups of mice.
The data suggest that FP might be useful in the reduction of ischemia-induced infarct volume when administered prior to the initiation of ischemia with no effect observed after ischemia induction.
Liposomes for drug delivery in stroke
2019, Brain Research Bulletin
Stroke is one of the leading causes of mortality and morbidity worldwide. Due to its poor prognosis, there is a major negative impact on the patients and their family’s life quality. However, despite the severity of this pathology tissue plasminogen activator (tPA) is the only FDA approved treatment for ischemic stroke. Moreover, there is no effective treatment for hemorrhagic stroke and only some palliative procedures are often performed to improve the patient's quality of life. Considering this, nanotechnology can offer some advantages for the development of new therapies for stroke. Among the various types of nanomaterials, liposomes are the most extensively studied due to their biocompatibility, biodegradability, and low toxicity. Liposomes, as a drug delivery system, are able to mask therapeutic compounds and allow their passage through the blood-brain barrier. Liposomes also protect drugs from degradation in a biological environment, increasing the circulation time and accumulation in the target tissue. Hence, this review highlights the potential of liposomes applications for delivery of therapeutic compounds for treating stroke.
The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach
2019, Neuropharmacology
Post-stroke depression (PSD) is a common and serious complication following stroke. Both stroke and depression have independently been associated with pathologically elevated glutamate levels in the brain's extra-cerebral fluid (ECF). Here we evaluate an alternative therapeutic approach to PSD with pyruvate. Rats were randomly assigned into one of 3 groups: Middle Cerebral Artery Occlusion (MCAO) plus pyruvate treatment, MCAO plus placebo treatment, and sham operated rats. Post-MCAO depressive and anxiety-like behavior was assessed, along with neurological status, brain infarct zone, brain edema, blood brain barrier (BBB) breakdown, cerebrospinal fluid and blood glutamate levels. Anxiety-like behavior and levels of blood alanine and α-ketoglutarate were measured in naïve rats treated with pyruvate, as a control. Post-stroke neurological deficit with concurrent elevation in glutamate levels were demonstrated, with peak glutamate levels 24 h after MCAO. Treatment with pyruvate led to reduced glutamate levels 24 h after MCAO and improved neurologic recovery. Pyruvate treatment reduced lesion volume, brain edema and the extent of BBB permeability 24 h post-MCAO. Naïve rats treated with pyruvate showed increased levels of α-ketoglutarate. Rats demonstrated post-stroke depressive behavior that was improved by the administration of pyruvate. There was less anxiety-like behavior in post-stroke rats treated with placebo in comparison to the post-stroke rats treated with pyruvate or sham operated rats. Glutamate scavenging with pyruvate appears to be an effective as a method in providing neuroprotection following stroke and as a therapeutic option for the treatment of PSD by reducing the consequent elevations in CNS glutamate levels.

View all citing articles on Scopus

View full text

ArticlesProgression of ischaemic stroke and excitotoxic aminoacids

Summary

Background

Methods

Findings

Interpretation

Introduction

Section snippets

Methods

Results

Discussion

Lancet

Comput Biomed Res

Trends Pharmacol Sci

Lancet

Deteriorating ischemic stroke: risk factors and prognosis

Neurology

Progressing neurological deficit secondary to acute ischemic stroke: a study on predictability, pathogenesis and prognosis

Arch Neurol

Progression of stroke after arrival at hospital

Stroke

Deterioration of acute stroke

Mechanisms of ischemic injury: is glutamate involved?

Pathophysiology and treatment of focal cerebral ischemia: part I: pathophysiology

J Neurosurg

Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised

Brain Pathol

Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbral region following middle cerebral artery occlusion in the rat: correlation with histopatahology

J Cereb Blood Flow Metab

Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion

Stroke

Elevation of neuroactive substances in the cortex of cats during prolonged focal ischemia

J Cereb Blood Flow Metab

Glycine potentiates the NMDA response in cultured mouse brain neurons

Nature

Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial

Stroke

Articles
Progression of ischaemic stroke and excitotoxic aminoacids